# Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers

> **NCT02706717** · PHASE2 · COMPLETED · sponsor: **Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections** · enrollment: 93 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Visbiome Extra Strength
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02706717
- **Lead sponsor:** Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2017-06-05
- **Final completion:** 2017-08-28
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2020-01-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02706717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02706717, "Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02706717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*